New Phase 2 trial data show benefits of elafibranor for PSC
Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
MET gene mutations could be rare cause of MASLD, MASH
Rare mutations in the MET gene can cause metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, a study found. After…
Surgery eases symptoms of rare skull condition in boy with Alagille
Craniosynostosis — a condition usually identified in infancy where the bones in a baby’s skull join together prematurely — led to elevated pressure in the…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
GLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…
Scotland to cover Iqirvo for eligible primary biliary cholangitis patients
The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…
Phase 3 trial of lanifibranor for MASH completes enrollment
Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a severe type of fatty…
Zetomipzomib brings steroid-sparing remission in autoimmune hepatitis
Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant autoimmune hepatitis, enabling them…
